Bergan Kdv Wealth Management, LLC Phathom Pharmaceuticals, Inc. Transaction History
Bergan Kdv Wealth Management, LLC
- $999 Million
- Q2 2023
A detailed history of Bergan Kdv Wealth Management, LLC transactions in Phathom Pharmaceuticals, Inc. stock. As of the latest transaction made, Bergan Kdv Wealth Management, LLC holds 140 shares of PHAT stock, worth $1,513. This represents 0.0% of its overall portfolio holdings.
Number of Shares
140Holding current value
$1,513% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding PHAT
# of Institutions
123Shares Held
54.7MCall Options Held
34KPut Options Held
58.7K-
Frazier Life Sciences Management, L.P. Menlo Park, CA10.1MShares$109 Million5.64% of portfolio
-
Medicxi Ventures Management (Jersey) LTD7.46MShares$80.7 Million20.79% of portfolio
-
Carlyle Group Inc. Washington, DC3.5MShares$37.8 Million2.73% of portfolio
-
Invesco Ltd. Atlanta, GA3.16MShares$34.2 Million0.01% of portfolio
-
Black Rock Inc. New York, NY2.75MShares$29.7 Million0.0% of portfolio
About Phathom Pharmaceuticals, Inc.
- Ticker PHAT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 39,175,200
- Market Cap $423M
- Description
- Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also develo...